排序方式:
    總頁 1 
      Go

    1.Concurrent use of herbal products with prescription drugs is a double-edged sword and evidence-based medicine contributes to reshaping the practice

    Leung, ELH, Wu, QB

    PHARMACOLOGICAL RESEARCH[1043-6618], Published 2019, Volume 141, Pages 609-610

    收錄情况: WOS SCOPUS

    WOS核心合集引用:  2023影響因子:  9.1  发表年影響因子:  5.893 

    2.Identification of an IKK beta inhibitor for inhibition of inflammation in vivo and in vitro

    Chen, Q, Liu, J, Zhu     More...

    PHARMACOLOGICAL RESEARCH[1043-6618], Published 2019, Volume 149,

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 14  2023影響因子:  9.1  发表年影響因子:  5.893 

    3.Artificial intelligence-based collaborative filtering method with ensemble learning for personalized lung cancer medicine without genetic sequencing

    Luo, Shengda, Liu, L     More...

    Pharmacological Research[1043-6618], Published 2020, Volume 160,

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 11  2023影響因子:  9.1  发表年影響因子:  7.658 

    4.Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway

    Xie, YaJia, Gao, Wei     More...

    Pharmacological Research[1043-6618], Published 2020, Volume 159,

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 26  2023影響因子:  9.1  发表年影響因子:  7.658 

    5.Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells

    Jiang, ZeBo, Xu, Con     More...

    Pharmacological Research[1043-6618], Published 2021, Volume 169,

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 17  2023影響因子:  9.1  发表年影響因子:  10.334 

    6.Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response

    Wang, Xuan-Run,Jiang     More...

    Pharmacological Research[1043-6618], Published 2022, Volume 179,

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 35  2023影響因子:  9.1  发表年影響因子:  9.3 

    7.β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.

    Xu, Cong, Jiang, Ze     More...

    Pharmacological Research[1043-6618], Published 2023, Volume 191,

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 29  2023影響因子:  9.1  发表年影響因子:  9.1 

    8.CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer.

    Wang, J, Li, RZ, Wan     More...

    PHARMACOLOGICAL RESEARCH[1043-6618], Published 2023, Volume 194,

    收錄情况: WOS SCOPUS

    WOS核心合集引用:  2023影響因子:  9.1  发表年影響因子:  9.1 

    顯示      條  合計   8   條
      總頁 1 
        Go

      本系統需要使用 Internet Explorer 9.0 以上Firefox || Chrome瀏覽器

      Copyright © 2018 澳門科技大學學者庫